Mode
Text Size
Log in / Sign up
N/A N=14 Other

MR Fingerprinting: A Novel Sequence Applied to Neuroimaging

Disease;Neurological

Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Jun 2023
Primary outcome: Primary: Percent of Participants With Visible Region of Interest (Imaging Visibility) — 100 percentage of participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
MR Fingerprinting (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of North Carolina, Chapel Hill
Primary completion
Aug 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent of Participants With Visible Region of Interest (Imaging Visibility)
100

Summary

Magnetic Resonance Imaging (MRI) has become one of most important medical imaging tools over the past 30 years because it is non-invasive, requires no ionizing radiation, and provides exquisite images of soft tissues and anatomic structures with many tissue/disease specific contrasts. While MRI has served the community well for many years, it is increasingly clear that it also has significant limitations. One of the principle limitations is the lack of quantitative information for tissue/structure characterization. The current paradigm of MRI is to use a set of scanner settings to generate an image "weighted" by a specific MR contrast mechanism (physical parameter), where it is hoped that variations in the parameter will be accentuated. However, without quantitative knowledge of the parameters, the final image contrast may depend on many factors, which complicates image interpretation and diagnostic performance. Quantitative measurement can provide a great deal of information about tissue properties and pathological conditions, since these parameters ultimately determine the contrast that is observed in conventional images.

Eligibility Criteria

Inclusion Criteria

  • The study will include English-speaking patients that are already scheduled to undergo a clinical neurological MRI for diagnostic purposes.

Exclusion Criteria

  • Pregnant women will be excluded.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03800537). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search